368 related articles for article (PubMed ID: 24530796)
21. G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly.
Lv X; He C; Huang C; Hua G; Wang Z; Remmenga SW; Rodabough KJ; Karpf AR; Dong J; Davis JS; Wang C
Mol Cancer Ther; 2017 Jun; 16(6):1080-1091. PubMed ID: 28258163
[TBL] [Abstract][Full Text] [Related]
22. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
23. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel class of tubulin inhibitors with promising anticancer activities.
Xi J; Zhu X; Feng Y; Huang N; Luo G; Mao Y; Han X; Tian W; Wang G; Han X; Luo R; Huang Z; An J
Mol Cancer Res; 2013 Aug; 11(8):856-64. PubMed ID: 23666368
[TBL] [Abstract][Full Text] [Related]
25. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
Bhattacharyya B; Panda D; Gupta S; Banerjee M
Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
[TBL] [Abstract][Full Text] [Related]
26. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
27. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
28. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
29. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
31. Novel fragment-derived colchicine-site binders as microtubule-destabilizing agents.
de la Roche NM; Mühlethaler T; Di Martino RMC; Ortega JA; Gioia D; Roy B; Prota AE; Steinmetz MO; Cavalli A
Eur J Med Chem; 2022 Nov; 241():114614. PubMed ID: 35939994
[TBL] [Abstract][Full Text] [Related]
32. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
[TBL] [Abstract][Full Text] [Related]
34. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
35. Electrostatic contributions to colchicine binding within tubulin isotypes.
Huzil JT; Barakat K; Tuszynski JA
Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
[TBL] [Abstract][Full Text] [Related]
36. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
37. Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.
Wang J; Miller DD; Li W
Drug Discov Today; 2022 Mar; 27(3):759-776. PubMed ID: 34890803
[TBL] [Abstract][Full Text] [Related]
38. Tools for the rational design of bivalent microtubule-targeting drugs.
Marangon J; Christodoulou MS; Casagrande FV; Tiana G; Dalla Via L; Aliverti A; Passarella D; Cappelletti G; Ricagno S
Biochem Biophys Res Commun; 2016 Oct; 479(1):48-53. PubMed ID: 27613098
[TBL] [Abstract][Full Text] [Related]
39. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
40. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
